Skip to main content

Advertisement

SpringerLink
Log in

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

  • Research Article
  • Published:
Tumor Biology

Abstract

We investigated the predictive value of decline in the serum levels of tumor markers on tumor response during the chemoradiotherapy (CRT) in patients with non-small cell lung cancer (NSCLC). The serum levels of cytokeratin 19 fragment antigen 21–1 (CYFRA21-1), neurone-specific enolase and carcinoembryonic antigen were measured by enzyme-linked immunosorbent assays, while the tumor responses were assessed according to the World Health Organization response criteria. The relationship between the changes of serum level of tumor markers and the radiologic response were analyzed. The effective rates (CR + PR) in CYFRA21-1 (pretreatment serum level) high and low groups were 45.8% (33/72) and 66.7% (24/36), respectively (p = 0.032). Independent sample t test showed that the relationship between the response of CYFRA21-1 and the radiologic objective response are significantly different (p = 0.008). The best cutoff value of the decline ratio of CYFRA21-1 was established as 18.48% by ROC curve. CYFRA 21–1 responses appeared to be reliable surrogate markers to predict chemoradiotherapy efficacy in patients with NSCLC, an average drop of 18.48% in serum CYFRA21-1 appears to provide the predictive information for the sensitivity of CRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ihde DC, Bunn PA, Hansen HH. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: how useful are they? J Clin Oncol. 1997;8:2996–3018.

    Google Scholar 

  2. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629–38.

    Article  PubMed  CAS  Google Scholar 

  3. Ebert W, Muley T. CYFRA 21–1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 1999;19:2669–72.

    PubMed  CAS  Google Scholar 

  4. van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW. Disease monitoring by tumour markers cyfra 21–1 and TPA in patients with non small cell lung cancer. Eur J Cancer. 1995;31A:1790–3.

    PubMed  Google Scholar 

  5. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys. 2001;51:56–61.

    PubMed  CAS  Google Scholar 

  6. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Clinical value of serum cytokeratin 19 fragment and Sialyl-Lewis X in non-small cell lung cancer. Ann Thorac Surg. 2007;83:216–21.

    Article  PubMed  Google Scholar 

  7. Holdenrieder S, Stieber P, Von Pawel J, Raith H, Nagel D, Feldmann K, et al. Early and specific prediction of therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragment. Ann NY Acad Sci. 2006;1075:244–57.

    Article  PubMed  CAS  Google Scholar 

  8. Mizuguchi S, Inoue K, Iwata T, et al. High serum concentrations of Sialyl Lewis(x) predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol. 2006;13:1010–8.

    Article  PubMed  Google Scholar 

  9. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer. 1995;13:169–76.

    Article  PubMed  CAS  Google Scholar 

  10. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21–1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097–105.

    PubMed  Google Scholar 

  11. Stieber P, Hasholzner U, Bodenmuller H, et al. CYFRA 21–1. A new marker in lung cancer. Cancer. 1993;72:707–13.

    Article  PubMed  CAS  Google Scholar 

  12. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178–84.

    PubMed  CAS  Google Scholar 

  13. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33:385–91.

    PubMed  CAS  Google Scholar 

  14. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157–64.

    Article  PubMed  CAS  Google Scholar 

  15. Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiothér. 2002;6:209–16.

    PubMed  CAS  Google Scholar 

  16. de Castro J, Rodríguez MC, Martínez-Zorzano VS, Hernández-Hernández A, Llanillo M, Sánchez-Yagüe J. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21–1. Cancer Investig. 2008;26:407–18.

    Article  Google Scholar 

  17. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer. 2007;58:369–75.

    Article  PubMed  Google Scholar 

  18. Buccheri G, Ferrigno D. Lung tumormarkers of cytokeratin origin: an overview. Lung Cancer. 2001;34 Suppl 2:S65–9.

    Article  PubMed  Google Scholar 

  19. Fischer JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer. 2004;45 Suppl 2:S151–161.

    Article  PubMed  Google Scholar 

  20. Plabani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improbe the results? Br J Cancer. 1995;72:170–3.

    Article  Google Scholar 

  21. Schalhorn A, Fuerst H, Stieber P. Tumor markers in lung cancer. J Lab Med. 2001;25:353–61.

    CAS  Google Scholar 

  22. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842–9.

    Article  PubMed  CAS  Google Scholar 

  23. Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res. 2003;23:5117–23.

    PubMed  CAS  Google Scholar 

  24. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA125, CYFRA 21–1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209–18.

    Article  PubMed  CAS  Google Scholar 

  25. Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21–1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357–62.

    Article  PubMed  Google Scholar 

  26. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629–38.

    Article  Google Scholar 

  27. Ochnio J, Rogińska E, Kwiek S, Rowinska-Zakrzewska E. Wartośćoznaczania poziomu antygenu karcinoembrionalnego w surowicy krwi dla rozpoznania raka płuca, oceny jego rozległości i określenia rokowania u chorych leczonych zachowawczo. Pneumonol Pol. 1984;52:313–9.

    PubMed  CAS  Google Scholar 

  28. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21–1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850–9.

    Article  PubMed  CAS  Google Scholar 

  29. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 1986;57:1318–23.

    Article  PubMed  CAS  Google Scholar 

  30. Buccheri G, Ferrigano D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19–9. Cancer. 1987;60:42–50.

    Article  PubMed  CAS  Google Scholar 

  31. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994;7:1350–64.

    Article  PubMed  CAS  Google Scholar 

  32. Lai R, Hsu H, Lu JY, Ger LP, Lai NS. CYFRA21-1 enzyme-linked immunosorbent assay. Chest. 1996;109:995–1000.

    Article  PubMed  CAS  Google Scholar 

  33. Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178–84.

    PubMed  CAS  Google Scholar 

  34. Bréchot JM, Chevret S, Nataf J, Le Gall C, Frétault J, Rochemaure J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumourmarkers in patients with non-small cell lung cancer: a prospective study. Eur J Cancer. 1997;33:385–91.

    PubMed  Google Scholar 

  35. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005;49:1–12.

    Article  PubMed  Google Scholar 

  36. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ. Christenson RH Serum CYFRA 21–1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728–33.

    PubMed  CAS  Google Scholar 

  37. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.

    Article  PubMed  CAS  Google Scholar 

  38. Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non–small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People’s Republic of China

    Juan Wang, Baosheng Li, Zhongtang Wang, Hongfu Sun, Yan Yi & Wei Huang

  2. Department of Joint Surgery, The First Hospital of Jilin University, Changchun, People’s Republic of China

    Ning Zhang

Authors
  1. Juan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baosheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhongtang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongfu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baosheng Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, J., Zhang, N., Li, B. et al. Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response. Tumor Biol. 32, 689–695 (2011). https://doi.org/10.1007/s13277-011-0169-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0169-2

Keywords

Search

Navigation